TY - JOUR
T1 - Changes in life expectancy for cancer patients over time since diagnosis
AU - Botta, Laura
AU - Dal Maso, Luigino
AU - Guzzinati, Stefano
AU - Panato, Chiara
AU - Gatta, Gemma
AU - Trama, Annalisa
AU - Rugge, Massimo
AU - Tagliabue, Giovanna
AU - Casella, Claudia
AU - Caruso, Bianca
AU - Michiara, Maria
AU - Ferretti, Stefano
AU - Sensi, Flavio
AU - Tumino, Rosario
AU - Toffolutti, Federica
AU - Russo, Antonio Giampiero
AU - Caiazzo, Anna Luisa
AU - Mangone, Lucia
AU - Mazzucco, Walter
AU - Iacovacci, Silvia
AU - Ricci, Paolo
AU - Gola, Gemma
AU - Candela, Giuseppa
AU - Sardo, Antonella Sutera
AU - De Angelis, Roberta
AU - Buzzoni, Carlotta
AU - Capocaccia, Riccardo
AU - Group, AIRTUM Working
PY - 2019/7/16
Y1 - 2019/7/16
N2 - The aims of this study were to provide life expectancy (LE) estimates of cancer patients at diagnosis and LE changes over time since diagnosis to describe the impact of cancer during patients' entire lives. Cancer patients' LE was calculated by standard period life table methodology using the relative survival of Italian patients diagnosed in population-based cancer registries in 1985-2011 with follow-up to 2013. Data were smoothed using a polynomial model and years of life lost (YLL) were calculated as the difference between patients' LE and that of the age- and sex-matched general population. The YLL at diagnosis was highest at the youngest age at diagnosis, steadily decreasing thereafter. For patients diagnosed at age 45 years, the YLL was above 20 for lung and ovarian cancers and below 6 for thyroid cancer in women and melanoma in men. LE progressively increased in patients surviving the first years, decreasing thereafter, to approach that of the general population. YLL in the long run mainly depends on attained age. Providing quantitative data is essential to better define clinical follow-up and plan health care resource allocation. These results help assess when the excess risk of death from tumour becomes negligible in cancer survivors.
AB - The aims of this study were to provide life expectancy (LE) estimates of cancer patients at diagnosis and LE changes over time since diagnosis to describe the impact of cancer during patients' entire lives. Cancer patients' LE was calculated by standard period life table methodology using the relative survival of Italian patients diagnosed in population-based cancer registries in 1985-2011 with follow-up to 2013. Data were smoothed using a polynomial model and years of life lost (YLL) were calculated as the difference between patients' LE and that of the age- and sex-matched general population. The YLL at diagnosis was highest at the youngest age at diagnosis, steadily decreasing thereafter. For patients diagnosed at age 45 years, the YLL was above 20 for lung and ovarian cancers and below 6 for thyroid cancer in women and melanoma in men. LE progressively increased in patients surviving the first years, decreasing thereafter, to approach that of the general population. YLL in the long run mainly depends on attained age. Providing quantitative data is essential to better define clinical follow-up and plan health care resource allocation. These results help assess when the excess risk of death from tumour becomes negligible in cancer survivors.
KW - (ICD-10), international classification of diseases tenth revision
KW - (ICD-O-3), international classification of diseases for oncology, third revision
KW - Cancer
KW - Cancer survivors
KW - ISTAT, national institute of statistics
KW - Italy
KW - LE, life expectancy
KW - Life expectancy
KW - NHL, non-Hodgkin lymphoma
KW - Population-based cancer registry
KW - RS, relative survival
KW - Relative survival
KW - YLL, years of life lost
U2 - 10.1016/j.jare.2019.07.002
DO - 10.1016/j.jare.2019.07.002
M3 - Article
VL - 20
SP - 153
EP - 159
JO - Journal of Advanced Research
JF - Journal of Advanced Research
SN - 2090-1232
ER -